Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP
Status:
Recruiting
Trial end date:
2022-07-08
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized clinical trial. During the study, non-HIV patients who are
admitted to ICU due to Pneumocystic pneumonia (PCP) and have not received anti-PCP therapy or
have received therapy less than 48hrs will be randomized (1:1) to received caspofungin
combined with trimethoprim-sulfamethoxazole or trimethoprim-sulfamethoxazole alone.
The aim of this study is to compare the effectiveness of caspofungin combined with
trimethoprim-sulfamethoxazole with that of conventional therapy
(trimethoprim-sulfamethoxazole alone) as first-line therapy in the treatment of severe
Pneumocystis pneumonia (PCP) in non-HIV patients.